Glioblastoma, often referred to as GBM, is one of the most aggressive forms of brain cancer. For patients and families, a GBM diagnosis is life-changing. Even with today’s standard treatment approaches, including surgery, radiotherapy, and chemotherapy, the disease remains extremely difficult to treat, and recurrence is a major challenge.

This is why new personalized approaches are urgently needed.

A recently published article in A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine, highlights an important step forward in the field of individualized cancer immunotherapy. The publication reports real-world data from 173 patients with glioblastoma who received personalized neoantigen-derived peptide vaccines. Alongside the scientific publication, a patient testimonial video from CeCaVa gives a human face to this work and shows what innovation can mean for an individual patient.

For Intavis Peptide Services, this story is especially meaningful. The personalized peptides used in this published work were synthesized by Intavis Peptide Services GmbH in Tuebingen, Germany.

Glioblastoma: A cancer with urgent unmet need

Glioblastoma is an incurable primary brain tumor with a very poor prognosis. For many patients, the standard first-line treatment consists of radiotherapy combined with temozolomide chemotherapy. While this treatment has been the backbone of GBM care for many years, outcomes remain limited, and recurrence is common.

Because GBM tumors are complex and vary from patient to patient, researchers and clinicians are increasingly exploring individualized treatment approaches. One promising strategy is the development of personalized cancer vaccines designed around the unique molecular profile of each patient’s tumor.

This is where personalized peptide vaccines come into focus.

A patient story that brings the science to life

In the CeCaVa's video, Rebecca shares her personal experience with glioblastoma. Her story is powerful because it moves beyond numbers, charts, and clinical terminology. It shows the human side of a disease that affects not only patients, but also families, friends, and entire communities.

Rebecca describes how she was once facing a devastating prognosis. Years later, she is still alive and able to share her story. Her experience is deeply personal and should not be understood as a guaranteed outcome for every patient. However, it does show why continued research, clinical development, and access to innovative personalized approaches matter so much.

Patient stories like Rebecca’s are important because they remind us what is at stake. Behind every tumor sample, sequencing result, peptide synthesis order, and vaccine preparation is a person hoping for more time, more options, and a better future.

Personalized neoantigen-derived peptide vaccines are designed individually for each patient

The process begins with analysis of the patient’s tumor. Researchers identify tumor-specific mutations and use this information to predict neoantigens: abnormal protein fragments that may be recognized by the immune system. Selected peptide sequences are then synthesized and formulated into a personalized vaccine.

The goal is to help the patient’s immune system recognize tumor-specific targets and activate T-cell responses against the cancer.

Unlike a one-size-fits-all treatment, this approach is tailored to the molecular profile of each patient’s tumor. That personalization makes the process scientifically complex and technically demanding. It also makes high-quality peptide synthesis a critical part of the workflow.

Key findings from the published real-world observation

This paper, A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine, reports on 173 patients with IDH-wildtype glioblastoma who received a personalized neoantigen-derived peptide vaccine between 2015 and 2023. Patients were treated within the scope of an individual healing attempt.

Several findings from the publication are especially important.

1. The study showed that producing and applying a personalized peptide vaccine for GBM patients was technically feasible in a real-world setting. The median time from tumor tissue acquisition to vaccine administration was 16 weeks, and vaccine administration could begin within 12 weeks after completion of tumor genomic sequencing.
2. The immune monitoring data were encouraging. Among patients with available post-vaccination immune monitoring, the majority developed vaccine-induced T-cell responses against at least one vaccinated peptide. This is an important signal because the purpose of the vaccine is to activate tumor-specific immune responses.
3. The safety profile reported in the paper was favorable. Adverse events attributed to the vaccine were infrequent and were predominantly grade 1 or 2. No grade 4 adverse events were observed.
4. The overall survival data were notable. Across the vaccinated cohort, the median overall survival from first diagnosis was reported as 31.9 months. Patients who developed multiple vaccine-induced T-cell responses showed longer survival compared with patients with no or low induced responses.

These findings make the publication an important contribution to the field of personalized cancer immunotherapy for GBM.

At the same time, the authors are careful to describe the work's limitations. This was a retrospective real-world observation, not a randomized controlled clinical trial. The patient population was heterogeneous, and patients received additional treatments based on the recommendations of their primary treating physicians. Therefore, the results show an important association, but further prospective clinical trials are needed to better evaluate the treatment effect.

From real-world evidence to future clinical development

The publication provides valuable real-world evidence for the feasibility, immunogenicity, and tolerability of personalized peptide vaccines in glioblastoma. It also provides a foundation for future clinical development.

This is an important next step. In oncology, especially in aggressive cancers such as GBM, promising real-world observations need to be followed by structured clinical investigation. Carefully designed clinical trials can help answer key questions about patient selection, treatment timing, immune response, safety, and clinical benefit.

The CeCaVa video and Rebecca’s story show the personal dimension of this work. The scientific paper shows the broader dataset behind the approach. Together, they highlight why collaboration between clinicians, researchers, biotechnology companies, and specialized peptide manufacturers is essential.

Intavis Peptide Services’ contribution

Behind every personalized peptide vaccine is a demanding manufacturing process.

For the published real-world observation, the peptides were synthesized by Intavis Peptide Services GmbH in Tuebingen, Germany. According to the publication, the peptides were produced by solid-phase peptide synthesis and purified to at least 95%. They were then used as part of the individualized vaccine workflow.

At Intavis Peptide Services, we are proud to contribute peptide synthesis expertise to projects where precision, quality, and reliability are essential. Personalized cancer vaccine programs require more than peptide production alone. They require close coordination, technical experience, and a strong understanding of the demands of individualized therapeutic approaches.

Our role in this work reflects what drives us as a peptide synthesis partner: supporting researchers, clinicians, and innovators who are advancing science in areas of high unmet medical need.

A story of science, collaboration, and hope

Rebecca’s story and the published real-world GBM data show what personalized medicine can make possible when science, clinical expertise, and specialized peptide manufacturing come together. While further clinical development is needed to fully understand the potential of personalized peptide vaccines, this work highlights an important direction for individualized cancer immunotherapy. INTAVIS Peptide Services is proud to have contributed through the synthesis of personalized peptides used in the published vaccine approach, supporting a program where precision, quality, and reliability are essential.

If you are developing personalized therapies, cancer vaccines, diagnostic applications, or peptide-based research programs and are looking for an experienced peptide synthesis partner, we would be happy to support you. From custom peptide synthesis and high-purity production to reliable project handling and expert technical support, Intavis Peptide Services helps turn complex peptide requirements into dependable results.

Feel free to contact us by email to discuss your next peptide project.

info@intavispeptides.com